Literature DB >> 2923862

Correlation of the dispersion state of pyrene cerebroside sulfate and its uptake and degradation by cultured cells.

P Viani1, S Marchesini, B Cestaro, S Gatt.   

Abstract

This study aimed at increasing the efficiency and shortening the time required for administering cerebroside sulfate to cultured cells. For this purpose several modes of dispersion of a fluorescent derivative of cerebroside sulfate (sulfatide), in which the natural fatty acid has been replaced by pyrenedodecanoic acid (P12), were incubated with the cells. This fluorescent derivative of cerebroside sulfate (P12-CS) was introduced into the growth medium of the cells using the three following modes of dispersion: (1) P12-CS was dissolved in dimethylsulfoxide and added to the medium, (2) it was precomplexed with serum albumin or (3) incorporated into small, unilamellar vesicles (SUV) of phosphatidylcholine. With each of these respective modes of dispersion, the P12-CS was incubated for periods up to 48 h with cultured lymphoblasts or fibroblasts. Uptake by the cells could be determined by recording directly the cell-associated fluorescence, using a suspension of washed intact cells. The cell lipids were subsequently extracted with mixtures of chloroform/methanol and their fluorescence recorded. When related to the incubation time, uptake of P12-CS by the cells increased continuously using each of the above dispersions. The appearance of fluorescence at 475 nm ('excimer') and the ratio of this to the monomolecular fluorescence at 378 nm ('E/M') could be used as a measure for the presence of the internalized P12-CS in aggregated or fully dispersed states. These values (i.e., E/M), recorded on the suspensions of intact cells were rather high using the aqueous dispersions, intermediate values were observed using the SUV and rather low E/M values (0.5 or less) were observed using the preformed albumin-(P12-CS) complexes. Increasing the mole ratio of albumin to P12-CS (i.e., from 1:2 to 2:1 m/m), decreased the quantity of sulfatide which was taken up by the cells but also further decreased the E/M ratio, suggesting a fully dispersed state of the pyrene lipid within the cell. This indicated that, using an optimal albumin to P12-CS ratio of 1-2 (or its equivalent values in fetal calf serum) permitted an influx of single molecules of P12-CS into the cells. After 48 h, about 50% of the fluorescence of skin fibroblasts was found in metabolic degradation products of P12-CS. The parallel value for fibroblasts derived from a patient with metachromatic leukodystrophy was only about 5%. Appearance of the excimeric emission of a dispersion of P12-CS in water permitted estimation of its critical micellar concentration as being 7.5 x 10(-7) M.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2923862     DOI: 10.1016/0005-2760(89)90059-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  High residual arylsulfatase A (ARSA) activity in a patient with late-infantile metachromatic leukodystrophy.

Authors:  J Kreysing; W Bohne; C Bösenberg; S Marchesini; J C Turpin; N Baumann; K von Figura; V Gieselmann
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

2.  Functional compartments of sulphatide metabolism in cultured living cells: evidence for the involvement of a novel sulphatide-degrading pathway.

Authors:  M C Tempesta; R Salvayre; T Levade
Journal:  Biochem J       Date:  1994-02-01       Impact factor: 3.857

3.  Laminin-sulfatide binding initiates basement membrane assembly and enables receptor signaling in Schwann cells and fibroblasts.

Authors:  Shaohua Li; Patricia Liquari; Karen K McKee; David Harrison; Raj Patel; Sean Lee; Peter D Yurchenco
Journal:  J Cell Biol       Date:  2005-04-11       Impact factor: 10.539

4.  Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells.

Authors:  Alessandra Biffi; Michele De Palma; Angelo Quattrini; Ubaldo Del Carro; Stefano Amadio; Ilaria Visigalli; Maria Sessa; Stefania Fasano; Riccardo Brambilla; Sergio Marchesini; Claudio Bordignon; Luigi Naldini
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.